RET and medullary thyroid gland carcinoma: According to the revised 2015 American Thyroid Association (ATA) guidelines, mutations at residues C6341 and A88311 are classed as high risk while the M918T mutation is classed as highest risk, in terms of developing MTC, with all other MEN2A variants classified as moderate risk1.